DK2509593T3 - Protein-polymer-konjugater - Google Patents

Protein-polymer-konjugater Download PDF

Info

Publication number
DK2509593T3
DK2509593T3 DK10836693.1T DK10836693T DK2509593T3 DK 2509593 T3 DK2509593 T3 DK 2509593T3 DK 10836693 T DK10836693 T DK 10836693T DK 2509593 T3 DK2509593 T3 DK 2509593T3
Authority
DK
Denmark
Prior art keywords
polymer conjugates
protein polymer
protein
conjugates
polymer
Prior art date
Application number
DK10836693.1T
Other languages
English (en)
Inventor
Ko-Chung Lin
Rudolf Dr Widmann
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Application granted granted Critical
Publication of DK2509593T3 publication Critical patent/DK2509593T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK10836693.1T 2009-12-10 2010-12-09 Protein-polymer-konjugater DK2509593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
PCT/US2010/059714 WO2011072138A2 (en) 2009-12-10 2010-12-09 Therapeutic use of protein-polymer conjugates

Publications (1)

Publication Number Publication Date
DK2509593T3 true DK2509593T3 (da) 2020-05-11

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10836693.1T DK2509593T3 (da) 2009-12-10 2010-12-09 Protein-polymer-konjugater

Country Status (32)

Country Link
US (1) US8617532B2 (da)
EP (1) EP2509593B1 (da)
JP (1) JP5547816B2 (da)
KR (1) KR101782084B1 (da)
CN (1) CN102724980B (da)
AR (1) AR079369A1 (da)
AU (1) AU2010328067B2 (da)
BR (1) BR112012014017B1 (da)
CA (1) CA2782624C (da)
CL (1) CL2012001503A1 (da)
CY (1) CY1122901T1 (da)
DK (1) DK2509593T3 (da)
EA (1) EA022354B9 (da)
ES (1) ES2786025T3 (da)
HR (1) HRP20200678T1 (da)
HU (1) HUE049051T2 (da)
IL (1) IL220249A0 (da)
LT (1) LT2509593T (da)
MA (1) MA33913B1 (da)
MX (1) MX337705B (da)
MY (1) MY169961A (da)
NZ (1) NZ600528A (da)
PL (1) PL2509593T3 (da)
PT (1) PT2509593T (da)
RS (1) RS60336B1 (da)
SG (1) SG181084A1 (da)
SI (1) SI2509593T1 (da)
SM (1) SMT202000239T1 (da)
TN (1) TN2012000256A1 (da)
UA (1) UA109646C2 (da)
WO (1) WO2011072138A2 (da)
ZA (1) ZA201205056B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05509B1 (et) * 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Also Published As

Publication number Publication date
CN102724980A (zh) 2012-10-10
CL2012001503A1 (es) 2012-11-09
BR112012014017A2 (pt) 2016-04-12
KR20120110105A (ko) 2012-10-09
SG181084A1 (en) 2012-07-30
CY1122901T1 (el) 2021-05-05
LT2509593T (lt) 2020-05-25
MX337705B (es) 2016-03-15
TN2012000256A1 (en) 2013-12-12
EA022354B1 (ru) 2015-12-30
AU2010328067B2 (en) 2014-10-02
EP2509593B1 (en) 2020-02-12
HUE049051T2 (hu) 2020-09-28
MX2012006132A (es) 2012-06-19
KR101782084B1 (ko) 2017-09-26
PL2509593T3 (pl) 2020-08-24
WO2011072138A9 (en) 2011-10-06
CN102724980B (zh) 2014-10-15
SI2509593T1 (sl) 2020-07-31
EP2509593A2 (en) 2012-10-17
IL220249A0 (en) 2012-07-31
MY169961A (en) 2019-06-19
CA2782624C (en) 2016-11-01
JP5547816B2 (ja) 2014-07-16
EA022354B9 (ru) 2016-02-29
HRP20200678T1 (hr) 2020-10-02
HK1176015A1 (en) 2013-07-19
WO2011072138A2 (en) 2011-06-16
UA109646C2 (uk) 2015-09-25
US8617532B2 (en) 2013-12-31
ES2786025T3 (es) 2020-10-08
NZ600528A (en) 2014-01-31
EP2509593A4 (en) 2016-01-13
AR079369A1 (es) 2012-01-18
ZA201205056B (en) 2013-03-27
BR112012014017B1 (pt) 2021-10-26
RS60336B1 (sr) 2020-07-31
EA201200865A1 (ru) 2012-11-30
JP2013513611A (ja) 2013-04-22
CA2782624A1 (en) 2011-06-16
US20110262380A1 (en) 2011-10-27
PT2509593T (pt) 2020-04-21
SMT202000239T1 (it) 2020-07-08
AU2010328067A1 (en) 2012-07-05
MA33913B1 (fr) 2013-01-02

Similar Documents

Publication Publication Date Title
DK2437790T3 (da) Konjugeringsfremgangsmåder
EP2406399A4 (en) MIRAC PROTEINS
DK3254678T3 (da) Multifunktionelle zwitterioniske polymerkonjugater
EP2480230A4 (en) DR5 Ligand-HEILMITTELKONJUGATE
DK2627713T3 (da) Polymerblandinger
DK2411442T4 (da) Umættet polyesterresin
DE112010002949A5 (de) Kupplungstastpunkte
EP2401340A4 (en) VERBUNDPOLYMERMODIFIKATOREN
EP2440486A4 (en) CABLE RETRACTION SYSTEM
BR112012001930A2 (pt) composição termoplástica
BR112012001747A2 (pt) composição termoplástica
DE112010002728A5 (de) Turboinhalator
BR112012015256A2 (pt) composição termoplastica
EP2478049A4 (en) POLYMER CARRIER
DE112009005323A5 (de) Hebelarmprüfmaschine
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
DE112010004865T8 (de) Lamellennassreibkupplung
BRPI1007245A2 (pt) composição polimérica
DE112010003255A5 (de) Fördergutverteiler
EP2441802A4 (en) II-CONJUGATED POLYMERIC COMPOSITION
ES1070429Y (es) Traspaleta mejorada
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
EP2504021A4 (en) Polypeptide conjugate
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas